Schrödinger delivered strong second-quarter results, with total revenue reaching $54.8 million, a 16% increase from the prior year. Software revenue grew by 15% to $40.5 million, and drug discovery revenue increased by 19% to $14.2 million. Despite a net loss of $43.2 million, the company's operating expenses decreased, and it reaffirmed its full-year revenue guidance while lowering operating expense projections. Key clinical milestones were also achieved, with encouraging initial data for SGR-1505 and expected data for SGR-3515 and SGR-2921 in Q4 2025.